JACC:肌腱蛋白C有保护超负荷后心肌再重塑作用

2017-09-21 MedSci MedSci原创

肌腱蛋白C(TNC)是一类在发育和疾病过程中高度保守的有特定表达模式的基质蛋白,而压力负荷过重后的左室重塑会引起一些致命基因重表达。近日,在国际心血管权威杂志JACC上发表了一篇旨在评估TNC在压力负荷过重后心肌肥厚发生过程中作用的研究。本研究通过环缩腹主动脉在TNC敲除小鼠和野生型对照小鼠中构建了压力超负荷模型,并通过心超、免疫染色、细胞流式、定量PCR和骨髓移植等一些列实验评估TNC敲除后的影

肌腱蛋白C(TNC)是一类在发育和疾病过程中高度保守的有特定表达模式的基质蛋白,而压力负荷过重后的左室重塑会引起一些致命基因重表达。近日,在国际心血管权威杂志JACC上发表了一篇旨在评估TNC在压力负荷过重后心肌肥厚发生过程中作用的研究。

本研究通过环缩腹主动脉在TNC敲除小鼠和野生型对照小鼠中构建了压力超负荷模型,并通过心超、免疫染色、细胞流式、定量PCR和骨髓移植等一些列实验评估TNC敲除后的影响。心超结果提示,TNC敲除小鼠的所有左室参数(左室舒张末期收缩指数、射血分数和缩短分数)较同窝对照均更恶化。心肌细胞大小和胶原沉积在TNC敲除小鼠中更明显。通过进一步的机制研究发现,TNC敲除后会引起CCR2 + / ly6chi单核/巨噬细胞亚群向心肌聚集。此外,免疫组化分析结果显示保护负荷过重后心脏重塑的是骨髓中的TNC,而非心肌TNC。

研究结果显示,TNC敲除后会进一步恶化负荷过重后心脏的重塑,并且通过引起炎症反应加重心肌纤维化。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1813534, encodeId=80c7181353439, content=<a href='/topic/show?id=c21a92930ba' target=_blank style='color:#2F92EE;'>#超负荷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92930, encryptionId=c21a92930ba, topicName=超负荷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 01 10:34:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853783, encodeId=17f11853e8347, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Feb 07 10:34:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807791, encodeId=1a2d180e79126, content=<a href='/topic/show?id=52578105249' target=_blank style='color:#2F92EE;'>#肌腱蛋白C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81052, encryptionId=52578105249, topicName=肌腱蛋白C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Tue May 01 21:34:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055180, encodeId=1fef20551800b, content=<a href='/topic/show?id=091688615da' target=_blank style='color:#2F92EE;'>#蛋白C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88615, encryptionId=091688615da, topicName=蛋白C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Thu Jan 11 18:34:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325533, encodeId=4beb132553392, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Sep 23 10:34:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512602, encodeId=825f1512602a6, content=<a href='/topic/show?id=b5cf81043ed' target=_blank style='color:#2F92EE;'>#肌腱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81043, encryptionId=b5cf81043ed, topicName=肌腱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6810483958, createdName=丁鹏鹏, createdTime=Sat Sep 23 10:34:00 CST 2017, time=2017-09-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1813534, encodeId=80c7181353439, content=<a href='/topic/show?id=c21a92930ba' target=_blank style='color:#2F92EE;'>#超负荷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92930, encryptionId=c21a92930ba, topicName=超负荷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 01 10:34:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853783, encodeId=17f11853e8347, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Feb 07 10:34:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807791, encodeId=1a2d180e79126, content=<a href='/topic/show?id=52578105249' target=_blank style='color:#2F92EE;'>#肌腱蛋白C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81052, encryptionId=52578105249, topicName=肌腱蛋白C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Tue May 01 21:34:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055180, encodeId=1fef20551800b, content=<a href='/topic/show?id=091688615da' target=_blank style='color:#2F92EE;'>#蛋白C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88615, encryptionId=091688615da, topicName=蛋白C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Thu Jan 11 18:34:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325533, encodeId=4beb132553392, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Sep 23 10:34:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512602, encodeId=825f1512602a6, content=<a href='/topic/show?id=b5cf81043ed' target=_blank style='color:#2F92EE;'>#肌腱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81043, encryptionId=b5cf81043ed, topicName=肌腱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6810483958, createdName=丁鹏鹏, createdTime=Sat Sep 23 10:34:00 CST 2017, time=2017-09-23, status=1, ipAttribution=)]
    2018-02-07 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1813534, encodeId=80c7181353439, content=<a href='/topic/show?id=c21a92930ba' target=_blank style='color:#2F92EE;'>#超负荷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92930, encryptionId=c21a92930ba, topicName=超负荷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 01 10:34:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853783, encodeId=17f11853e8347, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Feb 07 10:34:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807791, encodeId=1a2d180e79126, content=<a href='/topic/show?id=52578105249' target=_blank style='color:#2F92EE;'>#肌腱蛋白C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81052, encryptionId=52578105249, topicName=肌腱蛋白C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Tue May 01 21:34:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055180, encodeId=1fef20551800b, content=<a href='/topic/show?id=091688615da' target=_blank style='color:#2F92EE;'>#蛋白C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88615, encryptionId=091688615da, topicName=蛋白C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Thu Jan 11 18:34:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325533, encodeId=4beb132553392, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Sep 23 10:34:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512602, encodeId=825f1512602a6, content=<a href='/topic/show?id=b5cf81043ed' target=_blank style='color:#2F92EE;'>#肌腱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81043, encryptionId=b5cf81043ed, topicName=肌腱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6810483958, createdName=丁鹏鹏, createdTime=Sat Sep 23 10:34:00 CST 2017, time=2017-09-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1813534, encodeId=80c7181353439, content=<a href='/topic/show?id=c21a92930ba' target=_blank style='color:#2F92EE;'>#超负荷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92930, encryptionId=c21a92930ba, topicName=超负荷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 01 10:34:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853783, encodeId=17f11853e8347, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Feb 07 10:34:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807791, encodeId=1a2d180e79126, content=<a href='/topic/show?id=52578105249' target=_blank style='color:#2F92EE;'>#肌腱蛋白C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81052, encryptionId=52578105249, topicName=肌腱蛋白C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Tue May 01 21:34:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055180, encodeId=1fef20551800b, content=<a href='/topic/show?id=091688615da' target=_blank style='color:#2F92EE;'>#蛋白C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88615, encryptionId=091688615da, topicName=蛋白C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Thu Jan 11 18:34:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325533, encodeId=4beb132553392, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Sep 23 10:34:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512602, encodeId=825f1512602a6, content=<a href='/topic/show?id=b5cf81043ed' target=_blank style='color:#2F92EE;'>#肌腱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81043, encryptionId=b5cf81043ed, topicName=肌腱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6810483958, createdName=丁鹏鹏, createdTime=Sat Sep 23 10:34:00 CST 2017, time=2017-09-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1813534, encodeId=80c7181353439, content=<a href='/topic/show?id=c21a92930ba' target=_blank style='color:#2F92EE;'>#超负荷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92930, encryptionId=c21a92930ba, topicName=超负荷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 01 10:34:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853783, encodeId=17f11853e8347, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Feb 07 10:34:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807791, encodeId=1a2d180e79126, content=<a href='/topic/show?id=52578105249' target=_blank style='color:#2F92EE;'>#肌腱蛋白C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81052, encryptionId=52578105249, topicName=肌腱蛋白C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Tue May 01 21:34:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055180, encodeId=1fef20551800b, content=<a href='/topic/show?id=091688615da' target=_blank style='color:#2F92EE;'>#蛋白C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88615, encryptionId=091688615da, topicName=蛋白C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Thu Jan 11 18:34:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325533, encodeId=4beb132553392, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Sep 23 10:34:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512602, encodeId=825f1512602a6, content=<a href='/topic/show?id=b5cf81043ed' target=_blank style='color:#2F92EE;'>#肌腱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81043, encryptionId=b5cf81043ed, topicName=肌腱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6810483958, createdName=丁鹏鹏, createdTime=Sat Sep 23 10:34:00 CST 2017, time=2017-09-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1813534, encodeId=80c7181353439, content=<a href='/topic/show?id=c21a92930ba' target=_blank style='color:#2F92EE;'>#超负荷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92930, encryptionId=c21a92930ba, topicName=超负荷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 01 10:34:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853783, encodeId=17f11853e8347, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Feb 07 10:34:00 CST 2018, time=2018-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807791, encodeId=1a2d180e79126, content=<a href='/topic/show?id=52578105249' target=_blank style='color:#2F92EE;'>#肌腱蛋白C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81052, encryptionId=52578105249, topicName=肌腱蛋白C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Tue May 01 21:34:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055180, encodeId=1fef20551800b, content=<a href='/topic/show?id=091688615da' target=_blank style='color:#2F92EE;'>#蛋白C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88615, encryptionId=091688615da, topicName=蛋白C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f2c2500194, createdName=446798725_87912765, createdTime=Thu Jan 11 18:34:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325533, encodeId=4beb132553392, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Sep 23 10:34:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512602, encodeId=825f1512602a6, content=<a href='/topic/show?id=b5cf81043ed' target=_blank style='color:#2F92EE;'>#肌腱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81043, encryptionId=b5cf81043ed, topicName=肌腱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6810483958, createdName=丁鹏鹏, createdTime=Sat Sep 23 10:34:00 CST 2017, time=2017-09-23, status=1, ipAttribution=)]
    2017-09-23 丁鹏鹏

相关资讯

觉得世界对不起你?去走路吧!你的心脏、血管会感谢你!

走路是最不受时空限制、想到就能起身实践的行动。好消息是,每天走路去搭公交车、步行到巷口买早餐……透过日常通勤、采买等过程中少量多次的步行,效果跟长时间运动一样好。

Chest:手术治疗阻塞性睡眠呼吸暂停对心血管结局的影响

大量小规模和观察性研究的现有数据表明,OSA的外科治疗可能会改善某些心血管终点。

同型半胱氨酸为什么备受推崇

同型半胱胺酸是一种氨基酸,它是制造甲硫胺酸 (人体基本胱胺酸) 过程所需要的甲烷基的前驱体。同型半胱胺酸是我们消化动物蛋白的副产品,正常人的含量应该在 14μmol/L 以下。某些遗传因素或营养素的失调,会导致体内同型半胱胺酸的过度制造,它在体内浓度过高的结果,容易引发心脏血管方面的疾病,如心肌梗塞、脑中风、甚至阿兹海默氏症等。

JACC:下腔静脉滤过器的有效性和安全性研究

下腔静脉滤过器被广泛用来预防肺动脉栓塞(PE)的发生,然而,这种装置的长期安全性和有效性尚未阐明。近日,在国际心血管权威杂志JACC上发表了一篇旨在评估下腔静脉滤过器有效性和安全性的荟萃分析。本研究搜索了截至2016年10月3日PubMed, the Cochrane Central Register of Controlled Trials和ClinicalTrials.gov数据库的相关随机对

Lancet:多学科讨论:PURE研究“人应该多吃肉少吃主食”颠覆膳食观?

传统观点认为,低脂饮食才是王道,此外,饱和脂肪酸也被视为一大“健康杀手”。但2017年8月,发表在《Lancet》的一项研究竟告诉我们:碳水化合物摄入量过高会增加死亡风险,而总脂肪和各类脂肪却与较低的总死亡风险相关。

JACC:房颤患者接受达比加群抗凝治疗的持续性研究

对于房颤患者,指南推荐患者接受长期的口服抗凝治疗以预防卒中的发生。然而,在接受维生素K抗凝治疗的房颤患者中,药物中断率较高,接受其他非维生素K治疗患者的药物中断率可能较低。本研究纳入了新近诊断为房颤并有≥1个卒中高危因素的患者,对其进行随访2年。达比加群治疗非持续性定义为药物中断长达30天以上。最终共纳入2932名合格的患者,平均年龄为70.3 ± 10.2岁,男性占55.3%。在2年的随访期间,